Herm Rosenman served as our Chief Financial Officer from February 2014 to January 2017, and has served as a member of our board of directors since February 2017. Prior to joining our company, he held the position of Senior Vice President—Finance and Chief Financial Officer at Gen-Probe Incorporated, a developer, manufacturer and marketer of nucleic acid probe-based products used for the clinical diagnosis of human diseases and for screening donated human blood, from June 2001 to April 2012, when Gen-Probe was acquired by Hologic, Inc., a developer, manufacturer and supplier of diagnostic products, medical imaging systems, and surgical products. From April 2012 to February 2014, Mr. Rosenman focused on his board memberships. Prior to joining Gen-Probe, he was President and Chief Executive Officer of Ultra Acquisition Corp., a retail chain and consumer products manufacturer, from 1997 to 2000. Mr. Rosenman has served on the board of directors of Oxford Immunotec Global PLC, a commercial stage diagnostics company, since2013. Mr. Rosenman served on the board of directors of Medistem, Inc., a stem cell therapy company, from 2013 to2014; ARYx Therapeutics Inc., a private drug discovery and development company, from 2006 to 2009; Infinity Pharmaceuticals, Inc., a drug discovery and development company, where he served as Chairman of the Audit Committee, from 2003 to 2007. He has also served on the board of directors of a number of privately held companies. Mr. Rosenman holds a B.B.A. in accounting and finance from Pace University and an M.B.A. in finance from the Wharton School of the University of Pennsylvania.
What is Herm Rosenman's net worth?
The estimated net worth of Herm Rosenman is at least $3.30 million as of May 9th, 2022. Mr. Rosenman owns 72,832 shares of Natera stock worth more than $3,300,018 as of February 7th. This net worth estimate does not reflect any other assets that Mr. Rosenman may own. Learn More about Herm Rosenman's net worth.
How do I contact Herm Rosenman?
Has Herm Rosenman been buying or selling shares of Natera?
Herm Rosenman has not been actively trading shares of Natera within the last three months. Most recently, Herm Rosenman sold 44,503 shares of the business's stock in a transaction on Monday, November 8th. The shares were sold at an average price of $29.37, for a transaction totalling $1,307,053.11. Learn More on Herm Rosenman's trading history.
Who are Natera's active insiders?
Natera's insider roster includes Roy Baynes (Director), Roelof Botha (Director), Michael Brophy (CFO), Rowan Chapman (Director), Steven Chapman (CEO), Todd Cozzens (Director), James Healy (Director), Gail Marcus (Director), Daniel Rabinowitz (Insider), Matthew Rabinowitz (Chairman), Herm Rosenman (Director), Robert Schueren (COO), and Jonathan Sheena (Insider). Learn More on Natera's active insiders.
Are insiders buying or selling shares of Natera?
During the last twelve months, Natera insiders bought shares 2 times. They purchased a total of 372,820 shares worth more than $11,323,786.80. During the last twelve months, insiders at the medical research company sold shares 62 times. They sold a total of 164,110 shares worth more than $6,807,068.72. The most recent insider tranaction occured on February, 1st when CFO Michael Burkes Brophy sold 19,326 shares worth more than $844,159.68. Insiders at Natera own 10.3% of the company.
Learn More about insider trades at Natera. Information on this page was last updated on 2/1/2023.